R62
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- MYOGENESIS+0.300
- ESTROGEN_RESPONSE_LATE+0.290
- KRAS_SIGNALING_DN+0.270
- PANCREAS_BETA_CELLS+0.270
- ESTROGEN_RESPONSE_EARLY+0.260
- APICAL_JUNCTION+0.240
- APICAL_SURFACE+0.220
- COAGULATION+0.200
- BILE_ACID_METABOLISM+0.170
Top 10 suppressed
- MYC_TARGETS_V1-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.430
- PROTEIN_SECRETION-0.420
- MYC_TARGETS_V2-0.410
- ANDROGEN_RESPONSE-0.390
- INTERFERON_ALPHA_RESPONSE-0.390
- MTORC1_SIGNALING-0.370
- G2M_CHECKPOINT-0.360
- TGF_BETA_SIGNALING-0.350
- OXIDATIVE_PHOSPHORYLATION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d93b1580-c20d-4611-ac99-c0cb33f37a45 | — | — | 0.887 |
| 2 | SRR1083100 | GTEX | — | 0.868 |
| 3 | SJEPD001525_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.866 |
| 4 | SRR1488651 | GTEX | — | 0.864 |
| 5 | TCGA-MP-A4TD-01A-32R-A262-07 | — | cohortA3 | 0.861 |
| 6 | SRR1340202 | GTEX | — | 0.858 |
| 7 | SRR1420215 | GTEX | — | 0.857 |
| 8 | TCGA-78-7535-01A-11R-2066-07 | — | cohortA1 | 0.857 |
| 9 | SRR4296064 | — | cohortA1 | 0.856 |
| 10 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |